The PI3K/AKT signaling pathway regulates glioma cell proliferation and invasion, while pharmacological inhibitors of PI3K/Akt signaling (LY294002 and A443654) reduce the motility of GBM cells and diminish the level of MMP-2 activity and MMP-2 expression (28,29). This evidence concerns the gene AKT1 and central nervous system cancer.